The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Hyperexpression of mitogen-activated protein kinase in human breast cancer.
Open accessAbstract
Mitogen-activated protein (MAP) kinases act as transducers of extracellular signaling via tyrosine kinase-growth factor receptors and G-protein-linked receptors to elements regulating transcription. The activity, abundance, and localization of MAP kinase was investigated in normal and malignant neoplasia of the breast. In carcinoma of the breast, MAP kinase was heavily phosphorylated on tyrosyl residues and its activity elevated 5-10-fold over benign conditions, such as fibroadenoma and fibrocystic disease. By in situ reverse transcription-polymerase chain reaction, hyperexpression of MAP kinase mRNA can be localized to malignant, epithelial cells. Metastatic cells within involved lymph nodes of patients with breast cancer also display hyperexpression of MAP kinase. In spite of persistent activation via phosphorylation, MAP kinase expression is upregulated 5-20-fold and this hyperexpression may be a critical element to initiation as well as the metastatic potential of various forms of human breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cobb, M. H., & Goldsmith, E. J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.25.14843 · Cited by 1,719
Wingo, P. A., Tong, T., & Bolden, S. (1995) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.45.1.8 · Cited by 1,410
Signal transduction via the MAP kinases: proceed at your own RSK.
Blenis, J. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.13.5889 · Cited by 1,243
Langdale, J. A. (1994) · The Maize Handbook · doi:10.1007/978-1-4612-2694-9_18 · Cited by 866
Brunet, A., Pagès, G., & Pouysségur, J. (1994) · PubMed · Cited by 219
MAP kinase is constitutively activated in gip2 and src transformed rat 1a fibroblasts.
Gupta, S. K., Gallego, C., Johnson, G. L., & Heasley, L. E. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42397-6 · Cited by 219
Arteaga, C. L., Johnson, M. D., Todderud, G., Coffey, R. J., Carpenter, G., & Page, D. L. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10435 · Cited by 205
Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2.
Janes, P. W., Daly, R. J., DeFazio, A., & Sutherland, R. L. (1994) · PubMed · Cited by 199
Nuovo, G. J., Forde, A., MacConnell, P., & Fahrenwald, R. (1993) · PubMed Central · Cited by 145
Self-citationAgonist Regulation of Gene Expression of Adrenergic Receptors and G Proteins
Hadcock, J. R., & Malbon, C. C. (1993) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1993.tb05816.x · Cited by 126
Self-citation
Cited by
Regulation of matrix metalloproteinase expression in tumor invasion
Westermarck, J., & Kähäri, V. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.8.781 · Cited by 1,494
Regulation of matrix metalloproteinases: An overview
Chakraborti, S., Mandal, M., Das, S., Mandal, A., & Chakraborti, T. (2003) · Molecular and Cellular Biochemistry · doi:10.1023/a:1026028303196 · Cited by 1,128
Targeting the mitogen-activated protein kinase cascade to treat cancer
Sebolt-Leopold, J. S., & Herrera, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1503 · Cited by 1,108
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 970
Filardo, E. J., Quinn, J. A., Frackelton, A. R., & Bland, K. I. (2002) · Molecular Endocrinology · doi:10.1210/me.16.1.70 · Cited by 904
Endocrine-responsive breast cancer and strategies for combating resistance
Ali, S., & Coombes, R. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc721 · Cited by 883
Terminal Differentiation of Human Breast Cancer through PPARγ
Mueller, E., Sarraf, P., Tontonoz, P., Evans, R. M., Martin, K. J., Zhang, M., Fletcher, C., Singer, S., & Spiegelman, B. M. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80047-7 · Cited by 851
Dual specificity phosphatases: a gene family for control of MAP kinase function
CAMPS, M., NICHOLS, A., & ARKINSTALL, S. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.1.6 · Cited by 811
P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase
Myers, M. P., Stolarov, J. P., Eng, C., Li, J., Wang, S. I., Wigler, M. H., Parsons, R., & Tonks, N. K. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.9052 · Cited by 775
Rho GTPases are over-expressed in human tumors
Fritz, G., Just, I., & Kaina, B. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990531)81:5<682::aid-ijc2>3.0.co;2-b · Cited by 659
Wang, F., Weaver, V. M., Petersen, O. W., Larabell, C. A., Dedhar, S., Briand, P., Lupu, R., & Bissell, M. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14821 · Cited by 653
Boutros, T., Chevet, E., & Metrakos, P. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.00106 · Cited by 545
Role of MAP kinase in tumor progression and invasion
Reddy, K. B., Nabha, S. M., & Atanaskova, N. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023781114568 · Cited by 509
Structural basis of inhibitor selectivity in MAP kinases
Wang, Z., Canagarajah, B. J., Boehm, J. C., Kassisà, S., Cobb, M. H., Young, P. R., Abdel-Meguid, S., Adams, J. L., & Goldsmith, E. J. (1998) · Structure · doi:10.1016/s0969-2126(98)00113-0 · Cited by 423
Thrombin receptor overexpression in malignant and physiological invasion processes
Even-Ram, S., Uziely, B., Cohen, P., Grisaru-Granovsky, S., Maoz, M., Ginzburg, Y., Reich, R., Vlodavsky, I., & Bar-Shavit, R. (1998) · Nature Medicine · doi:10.1038/nm0898-909 · Cited by 417
The role of mitogen-activated protein (MAP) kinase in breast cancer
Santen, R. J., Song, R. X., McPherson, R., Kumar, R., Adam, L., Jeng, M.-H., & Yue, W. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00189-3 · Cited by 406
Razandi, M. (2002) · Molecular Endocrinology · doi:10.1210/me.16.1.100 · Cited by 402
Fritz, G., Brachetti, C., Bahlmann, F., Schmidt, M., & Kaina, B. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600510 · Cited by 381
Filardo, E. J. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(01)00190-x · Cited by 373
Schnelzer, A., Prechtel, D., Knaus, U., Dehne, K., Gerhard, M., Graeff, H., Harbeck, N., Schmitt, M., & Lengyel, E. (2000) · Oncogene · doi:10.1038/sj.onc.1203621 · Cited by 347
Ito, Y., Sasaki, Y., Horimoto, M., Wada, S., Tanaka, Y., Kasahara, A., Ueki, T., Hirano, T., Yamamoto, H., Fujimoto, J., et al. (1998) · Hepatology · doi:10.1002/hep.510270409 · Cited by 334
Estrogen Receptor Alpha in Human Breast Cancer: Occurrence and Significance
Ali, S., & Coombes, R. C. (2000) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/a:1009594727358 · Cited by 329
The Ras/Raf/MEK/ERK signaling pathway and its role in the occurrence and development of HCC
Li, L., Zhao, G.-D., Shi, Z., Qi, L.-L., Zhou, L.-Y., & Fu, Z.-X. (2016) · Oncology Letters · doi:10.3892/ol.2016.5110 · Cited by 305
Martin, L.-A., Farmer, I., Johnston, S. R. D., Ali, S., Marshall, C., & Dowsett, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305226200 · Cited by 295
The functional contrariety of JNK
Bode, A. M., & Dong, Z. (2007) · Molecular Carcinogenesis · doi:10.1002/mc.20348 · Cited by 293
Jazirehi, A. R., & Bonavida, B. (2005) · Oncogene · doi:10.1038/sj.onc.1208349 · Cited by 275
B-Crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer
Moyano, J. V. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25888 · Cited by 272
Paradoxical activation of Raf by a novel Raf inhibitor
Hall-Jackson, C. A., Eyers, P. A., Cohen, P., Goedert, M., Tom Boyle, F., Hewitt, N., Plant, H., & Hedge, P. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80088-x · Cited by 265
CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)
ALLEN, L. (2003) · Seminars in Oncology · doi:10.1053/j.seminoncol.2003.08.012 · Cited by 257
Solution Structure of ERK2 Binding Domain of MAPK Phosphatase MKP-3
Farooq, A., Chaturvedi, G., Mujtaba, S., Plotnikova, O., Zeng, L., Dhalluin, C., Ashton, R., & Zhou, M.-M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00186-1 · Cited by 119
Chen, J. C., Zhuang, S., Nguyen, T. H., Boss, G. R., & Pilz, R. B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207943200 · Cited by 71
Callaway, K., Waas, W. F., Rainey, M. A., Ren, P., & Dalby, K. N. (2010) · Biochemistry · doi:10.1021/bi100199q · Cited by 32
Metadata
- Authors
- Sivaraman, V. S., Wang, H., Nuovo, G. J., & Malbon, C. C.
- Venue
- Journal of Clinical Investigation
- Published
- 1997-04-01
- Volume
- 99
- Issue
- 7
- Pages
- 1478-1483
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2052016477
- Cited by
- 451
- References
- 13
- FWCI
- 8.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.